A qualitative study of exploring and comparing the impact of discontinuation of tyrosine kinase inhibitors (TKI)/Imatinib vs continuing (TKI) Imatinib in childhood chronic myeloid leukemia (CML) patients: patients perspective

This study focuses on a rare type of blood cancer called Chronic Myeloid Leukemia (CML). The researchers want to learn how patients feel about their medicine, which is called Imatinib. Some patients have to take this medicine for a long time, and it can have side effects that affect their lives.

The researchers will talk to patients with CML who have either stopped taking the medicine or are still taking it. They want to understand how patients feel about stopping the medicine compared to those who continue with it. In this study, we will enroll patients who are in the age category of 18 to 39 years and were diagnosed with CML during their childhood.

The researchers will have friendly and relaxed interviews with the patients, asking about their experiences and thoughts related to the medicine. They want to learn if stopping the medicine makes the patients feel better or if it has any negative effects.

By listening to the patients’ stories, the researchers hope to find ways to improve the treatment for CML and make sure patients with this cancer have a better quality of life. The study will continue until the researchers have heard enough from the patients and have a good understanding of their experiences and feelings about the medicine.